Design, synthesis and biological evaluation of non-glucosidal based 1,3,4-thiadiazoles as SGLT-2 inhibitors

Future Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: Feb. 11, 2025

Type-2 diabetes mellitus (T2DM) is a major metabolic disorder needing insulin-independent treatments; this study developed Schiff base 1,3,4-thiadiazole as Sodium Glucose Co-transporters 2 (SGLT2) inhibitors. The target compounds were synthesized followed by docking studies, in vitro and vivo analysis. In assay revealed SSS 6 exhibited high SGLT2 inhibition activity i.e. 78.57% ± 2.8 74.60% 1.12 compared to dapagliflozin (93.65% 4.48) at same dosage enzyme assays. results reveals that significantly improved excretion of urinary glucose (854 46.51 mg/body weight) (775 32.68 weight. decreased blood levels (137 4.89 mg/dL 183 15.07 mg/dL) relative (158 15.9 mg/dL). Compounds emerge potential candidates for further investigation inhibitors treating T2DM.

Language: Английский

Unveiling the therapeutic potential of 1,2,4-oxadiazole derivatives: An updated review

Results in Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 102271 - 102271

Published: April 1, 2025

Language: Английский